Assess whether pediatric studies are necessary or waivable (e12535)

Situation

The desk packet is phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module. Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Pediatric studies are necessary / Waivable using phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• A CMO 483 that maps to the NDA CMC module is noise around an already-controlled CMC and Development Pathways process in a mid-size sponsor after a complete response letter, given phase-3 protocol with endpoint-sensitivity issues.
• A CMO 483 that maps to the NDA CMC module is the event in phase-3 protocol with endpoint-sensitivity issues that forces Pediatric studies are necessary for pharmacovigilance medical reviewer under Pharma & Life Sciences.
• Phase-3 protocol with endpoint-sensitivity issues shows a one-file miss after a CMO 483 that maps to the NDA CMC module, not a CMC and Development Pathways program failure.
• Phase-3 protocol with endpoint-sensitivity issues cannot decide pediatric studies are necessary yet after a CMO 483 that maps to the NDA CMC module; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a CMO 483 that maps to the NDA CMC module and write the one fact that would move pediatric studies are necessary for pharmacovigilance medical reviewer.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.